Every 10-Q that GeneDx Holdings Corp. (WGS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow WGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGS filings page.
GeneDx Holdings Corp. reported strong revenue growth but a sharply higher loss for the quarter ended March 31, 2026. Total revenue rose 17% to $102.3 million, driven by an 18% increase in diagnostic test revenue to $101.3 million as whole exome and genome volumes grew 34%.
Net loss widened to $63.3 million from $6.5 million a year earlier, or $2.16 per share, mainly due to $31.3 million of non‑cash impairment charges related to the Fabric Genomics unit and a $6.6 million loss on extinguishment of debt. Cash, cash equivalents and marketable securities totaled $170.7 million, helped by a new $100 million term loan from Blackstone, while operating cash flow was a $32.4 million outflow.
GeneDx Holdings (WGS) reported Q3 results showing strong top-line growth and improved profitability. Revenue rose to $116.7 million from $76.9 million, lifting gross profit to $84.5 million from $47.8 million. Loss from operations narrowed to $3.3 million from $7.8 million, and net loss was $7.6 million versus $8.3 million a year ago.
For the first nine months, revenue reached $306.6 million versus $209.8 million, with net loss improving to $3.4 million from $57.7 million. Cash and cash equivalents were $95.97 million, and marketable securities were $59.11 million as of September 30, 2025. The company closed the Fabric Genomics acquisition (aggregate purchase price $36.5 million), adding $12.8 million of goodwill and a $6.8 million contingent consideration liability; Fabric contributed $2.0 million of revenue in Q3.
Operating cash flow was $36.4 million year-to-date. Shares outstanding were 28,904,590 as of October 24, 2025; the company issued stock via its ATM in Q3 and year-to-date, raising $11.8 million and $25.6 million, respectively.